Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval.
Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval.
复制标题
DOI：
10.1136/bmjopen-2015-007702
复制
发表时间：
2015-04-29
期刊：
影响因子：
2.9
通讯作者：
Sørensen HT
中科院分区：
文献类型：
--
作者：
Cetin K;Christiansen CF;Sværke C;Jacobsen JB;Sørensen HT
由于目前影响乳腺癌骨转移（BM）患者生存率的预后因素的人群数据有限，我们进行了这项全国性的回顾性队列研究，以检查乳腺癌诊断时疾病分期和无BM间期（BMFI）长度的预后作用。丹麦。在1997年至2011年期间在丹麦癌症登记处诊断为乳腺癌并在丹麦国家患者登记处同时或随后诊断为BM的2427名女性。基于Kaplan-Meier方法和死亡风险的生存率（粗）根据乳腺癌诊断时的疾病分期和BMFI持续时间，基于考克斯比例风险回归分析（粗值和经年龄、诊断年份、雌激素受体状态和合并症调整）（从乳腺癌到BM诊断的时间），患者从BM诊断到死亡、移民或直到2012年12月31日，以先发生者为准。在乳腺癌诊断时，生存率随着疾病的晚期而降低; BM诊断后第一年内，转移性疾病患者的死亡风险比局限性疾病患者高两倍以上（校正HR=2.12（95% CI 1.71 - 2.62））。就BMFI的持续时间而言，BMFI <1年的女性（即在乳腺癌诊断时出现BM或在1年内诊断的女性）生存率最高。 然而，在BMFI ≥1年的患者中，生存率随着BMFI的延长而增加（1年生存率：BMFI 1至<3年为39.9%（95% CI 36.3%至43.6%），BMFI ≥5年为52.6%（95% CI 47.4%至57.6%））。 在多变量分析中也观察到这种模式。乳腺癌诊断时的疾病分期和BMFI的长度似乎是BM后生存的重要预后因素。
Since population-based data on prognostic factors affecting survival in patients with breast cancer with bone metastasis (BM) are currently limited, we conducted this nationwide retrospective cohort study to examine the prognostic role of disease stage at breast cancer diagnosis and length of BM-free interval (BMFI). Denmark. 2427 women with a breast cancer diagnosis between 1997 and 2011 in the Danish Cancer Registry and a concurrent or subsequent BM diagnosis in the Danish National Registry of Patients. Survival (crude) based on Kaplan-Meier method and mortality risk (crude and adjusted for age, year of diagnosis, estrogen receptor status and comorbidity) based on Cox proportional hazards regression analyses by stage of disease at breast cancer diagnosis and by length of BMFI (time from breast cancer to BM diagnosis), following patients from BM diagnosis until death, emigration or until 31 December 2012, whichever came first. Survival decreased with more advanced stage of disease at the time of breast cancer diagnosis; risk of mortality during the first year following a BM diagnosis was over two times higher for those presenting with metastatic versus localised disease (adjusted HR=2.12 (95% CI 1.71 to 2.62)). With respect to length of BMFI, survival was highest in women with a BMFI <1 year (ie, in those who presented with BM at the time of breast cancer diagnosis or were diagnosed within 1 year). However, among patients with a BMFI ≥1 year, survival increased with longer BMFI (1-year survival: 39.9% (95% CI 36.3% to 43.6%) for BMFI 1 to <3 years and 52.6% (95% CI 47.4% to 57.6%) for BMFI ≥5 years). This pattern was also observed in multivariate analyses. Stage of disease at breast cancer diagnosis and length of BMFI appear to be important prognostic factors for survival following BM.
登录
查看更多内容
影响因子：
3.8
作者：
Jensen AØ;Jacobsen JB;Nørgaard M;Yong M;Fryzek JP;Sørensen HT
通讯作者：
Sørensen HT
影响因子：
7.2
作者：
Newschaffer, CJ;Bush, TL;Penberthy, LT
通讯作者：
Penberthy, LT
影响因子：
3.4
作者：
Gjerstorff, Marianne Lundkjaer
通讯作者：
Gjerstorff, Marianne Lundkjaer
影响因子：
11.5
作者：
Coleman, Robert E.
通讯作者：
Coleman, Robert E.
影响因子：
3.9
作者：
Li S;Peng Y;Weinhandl ED;Blaes AH;Cetin K;Chia VM;Stryker S;Pinzone JJ;Acquavella JF;Arneson TJ
通讯作者：
Arneson TJ